Company type | Public |
---|---|
BSE: 500257 NSE: LUPIN | |
Industry | Pharmaceuticals |
Founded | 1968[1] |
Founder | Desh Bandhu Gupta[2] |
Headquarters | , India |
Key people | Vinita D. Gupta (CEO)[4] Nilesh Gupta (MD)[5][6] |
Products | |
Revenue | ₹19,656 crore (US$2.4 billion) (FY24)[7] |
₹3,800 crore (US$460 million) (FY24)[7] | |
₹1,914 crore (US$230 million) (FY24)[7] | |
Total assets | ₹22,955 crore (US$2.8 billion)[8] (2023) |
Total equity | ₹12,464 crore (US$1.5 billion)[8] (2023) |
Number of employees | 20,000+ (2023) |
Website | www |
Footnotes / references [9] |
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally.[10] The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.